Altera Digital Health Launches Sunrise CarePath Patient Engagement Platform
Research suggests approximately 20% of patients experience adverse events within three weeks of hospital discharge, many of which are preventable. To bolster patient-provider communication, during and beyond the critical post-discharge period, Sunrise CarePath includes on-demand messaging that connects patients to care team members. Enabling patients to quickly clarify discharge instructions and report side effects in real time will help prevent avoidable emergency department (ED) visits and readmissions while also supporting patient confidence and continuity of care.
Sunrise CarePath also offers instant appointment management and intelligent rescheduling/cancellation capabilities to help reduce missed appointments hindering proper medication management, timely interventions, care quality and hospital revenue. To further empower patients and encourage care plan adherence, Sunrise CarePath includes notifications for new health data and appointment reminders customized to the patient's communication preferences. Additionally, Sunrise CarePath integrates with hospital bill pay pages, enabling patients to pay medical bills in a paperless, convenient and secure manner. This removes friction from the patient financial experience and speeds up revenue collection, while also reducing administrative burdens for healthcare organizations.
"When patients can't easily message their care team, manage follow-up appointments or stay on track with medications, adverse events are inevitable,' said Jay Adams, Executive Vice President and General Manager for Sunrise, Altera Digital Health. 'Sunrise CarePath gives hospitals powerful tools to close these gaps—helping clinicians protect patients and drive better outcomes after discharge. This level of engagement is key to delivering truly patient-centric care.'
About Altera Digital Health
A global healthcare IT leader, Altera Digital Health develops and elevates technology to bring next-level healthcare within reach. Altera's approach to our solutions is changing the way healthcare is delivered—we see the summit of what healthcare can be, but rather than total transformation, we're focused on helping organizations take the steps they need to get there. Altera designs digital health services that lead healthcare to a higher place, while we guide those we partner with, all along the way. To learn more, visit www.alterahealth.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories. It also features its rapid next-generation sequencing (NGS) technology, recently approved by the U.S. Food and Drug Administration (FDA), the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer, for use as a companion diagnostic for Dizal's ZEGFROVY® (sunvozertinib) and for tumor profiling applications. 'Our solutions harness our scientific expertise to enhance care by enabling earlier and more precise detection and diagnosis. In partnership with our customers, we're working every day to bring better, faster and safer diagnostics to all patients,' said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. 'At Thermo Fisher, we are committed to advancing diagnostics that address today's most pressing global health challenges by boosting efficiency and reducing overall laboratory costs — ultimately driving more optimal patient care.' Harnessing Innovation for Quality Assurance, Efficiency and Sustainability in the Clinical Lab Clinical laboratories rely on quality assurance programs (QAPs) to ensure test result accuracy, which is essential for proper diagnosis and treatment. In resource-limited settings, a QAP that delivers quick, actionable insights can ease operational bottlenecks, improve workflow efficiency and enhance data-driven decisions. Thermo Fisher's new LabLink360 is a next-generation QAP software designed to help enhance patient safety, reduce errors and elevate healthcare quality. It features Sigma-metric analysis, a global benchmarking tool that helps labs assess performance and optimize quality control parameters based on results. Thermo Fisher also recently launched the Thermo Scientific MAS Omni•CORE ™ Max load-and-go quality controls (QC) to help simplify and automate lab workflows, allowing lab technicians to be more efficient and focus more on delivering fast and accurate patient results. The Omni•CORE Max QCs are part of a portfolio of QCs for clinical diagnostic testing, including the MAS Diabetes Max, which can help labs reduce daily QC bottles by up to 54% and lot-to-lot validations by up to 77%.** Beyond supporting the improved efficiency of laboratories, Thermo Fisher is also committed to supporting customers' sustainability initiatives. While most labs print patient results, QC, calibrations and other instrument data and place them in storage, this practice contributes to a staggering environmental impact. The company will present a poster and a micro-lecture explaining the transformative benefits of transitioning to a paperless laboratory environment. Targeting Unmet Diagnostic Needs Approximately 85% of patients in the U.S. receive cancer care in community settings. However, these sites have historically lacked consistent access to rapid and reliable next-generation sequencing, which is playing a growing role in informing precision oncology treatment decisions. At ADLM, the company will present its rapid NGS solution, the Oncomine Dx Express Test on the Ion Torrent Genexus Integrated Sequencer. Available as both an RUO solution and for clinical use on the Genexus Dx System, more care teams can now access NGS results in as little as 24 hours*** to help make more informed treatment recommendations for their patients, while also sparing patients from unnecessary delays, procedures and uncertainty. Also helping expand vital testing the company will highlight its PreClara™ Ratio,**** cleared in 2023 and previously known as B·R·A·H·M·S™ sFlt-1/PlGF KRYPTOR™ Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing. As the first FDA-cleared biomarker test for preeclampsia risk assessment, the PreClara Ratio provides reliable, quantifiable results with excellent analytical and clinical performance. When combined with other laboratory tests and standard clinical assessment, the PreClara Ratio may enable more informed clinical decisions, with the aim of improving health outcomes for both mothers and their babies. Thermo Fisher will also highlight its EXENT ® Solution, a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The EXENT Solution enables more sensitive analytical methods that can differentiate between patient subsets without requiring invasive bone marrow biopsy techniques too early. It is currently available for clinical use in Brazil, Belgium, France, Germany, Italy, the Netherlands, New Zealand, Spain, the United Kingdom, Switzerland and Australia. Thermo Fisher is also presenting its latest solutions for allergy and autoimmune diagnostics, oncology, women's health and quality control testing. In the booth, attendees can engage with a series of dynamic micro-lectures designed to advance industry knowledge and clinical expertise. These sessions cover a wide range of diagnostic topics and innovations, offering valuable insights into improving testing efficiency, patient outcomes and disease detection strategies. For more information on Thermo Fisher's activities at ADLM, please visit or conference booth (2812) to experience the full breadth of Thermo Fisher's diagnostic solutions. * Not yet commercially available. ** Will vary for each laboratory depending on the configuration. Data on file. ***Timing varies by number of samples and type of run. ****Brand trademarked in the U.S. only. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Business Wire
an hour ago
- Business Wire
Neogen® Expands its Pathogen Portfolio and Environmental Monitoring Solutions with a New Rapid Test for Listeria
LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG) today announced the launch of Molecular Detection Assay - Listeria Right Now™, a rapid, enrichment-free solution for detecting Listeria species in the environment. The new tool is being introduced at the 2025 International Association for Food Protection (IAFP) Annual Meeting, taking place July 27–30 at the Huntington Convention Center in Cleveland, Ohio. 'When it comes to Listeria, every hour counts. Listeria Right Now was designed to give food safety teams answers fast enough to act before a risk becomes a recall,' said Dr. Jason Lilly, Chief Scientific Officer at Neogen. Share With a time-to-result of approximately two hours, Listeria Right Now helps enable food safety professionals to make faster, more informed sanitation decisions without compromising accuracy or requiring complex laboratory infrastructure. 'When it comes to Listeria, every hour counts. Listeria Right Now was designed to give food safety teams answers fast enough to act before a risk becomes a recall,' said Dr. Jason Lilly, Chief Scientific Officer at Neogen. 'The method is precise, practical, and easy to deploy. We're excited to show how it can strengthen environmental monitoring programs in real-world settings.' Key Benefits of Listeria Right Now Streamlined, user-friendly testing process Delivers results in approximately two hours No enrichment required Uniquely designed sampling device that is easy to use for a variety of surface types Enables same-day verification and corrective response within two hours Built for Efficiency from Start to Finish Listeria Right Now pairs a user-friendly sample collection device designed to efficiently swab surfaces up to 12'x 12' and access narrow cracks and crevices, with an innovative reagent system. Each reaction tube includes blue, color-coded pellets that contain all of the reagents necessary for detection. These pellets reconstitute easily when pipetted, helping to streamline lab workflow and improve consistency. Listeria Right Now is powered by Neogen's Molecular Detection System, which features intuitive software, color-coded assays for better tracking, and the ability to test up to 96 samples per run. The system supports simultaneous testing across multiple qualitative assays, enabling labs to maintain workflow flexibility without added complexity. Solving Real-World Food Safety Challenges Traditional Listeria detection methods often require 24 to 48 hours and may involve multiple tools depending on surface type and testing needs. For processors in dairy, produce, beef, and ready-to-eat segments, these delays can disrupt workflows and elevate contamination risk. Listeria Right Now simplifies the detection process and enables interventions to happen during the same production shift. Built for global applicability, Listeria Right Now offers a practical, high-impact solution for diverse food production environments worldwide, while also supporting the evolving regulatory expectations around Listeria monitoring in the U.S. Live Demonstrations at IAFP 2025 Neogen will be showcasing Listeria Right Now at Booth #511 at IAFP 2025. Attendees can experience live demonstrations and speak with Neogen experts about how the system complements the company's broader food safety diagnostics portfolio. To learn more or schedule a demonstration, visit or contact your Neogen representative. About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Business Wire
an hour ago
- Business Wire
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared 1 by the FDA in the United States, following the feature's launch on Dexcom G7 earlier this year. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now simply take a photo of their food in the app where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the only prescription continuous glucose monitor in the U.S. to support photo logging 2,3. 'Diet plays a crucial role in managing glucose levels, and our new Smart Food Logging feature removes barriers to food tracking, making it easier to consistently log and understand the impact of meals,' said Jake Leach, president and chief operating officer at Dexcom. 'Smart Food Logging has long been a highly requested feature from users across our product portfolio, so we're excited to bring it to market and hope this enhanced tracking feature makes managing glucose levels even simpler.' The addition of Smart Food Logging is yet another demonstration of Dexcom's commitment to continued innovation and AI. This new feature joins other recently announced enhancements across Dexcom's glucose biosensing portfolio, including: Weekly Insights in Stelo: The first GenAI feature in Stelo, which offers users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app. Stelo integration with Oura: The first-ever integration of glucose biosensing data in the Oura app. When Stelo is synced with Oura, users have a holistic view of their body's biometrics, now including glucose. This integration empowers users to understand the impact of different health behaviors and work towards optimal metabolic health. Customizable target range in Dexcom G7: A new feature that enables users to adjust their glucose target ranges in Clarity Card within the Dexcom G7 app, beyond default settings – allowing for greater personalization across user groups. Glucose Impact in Dexcom G7 and Stelo: Glucose Impact offers a new focused view for logged events to see a clearer picture and gain a deeper understanding of how meals, activities, and sleep patterns affect your glucose levels. Stelo and Dexcom G7 users can now access the Smart Food Logging feature by updating to the latest version of the app on iOS and Android platforms. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR Freestyle Libre User Guides. 3 Based on Medtronic User Guides.
